A gene expression signature for high-risk multiple myeloma. (Q47590597)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22722715%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

A gene expression signature for high-risk multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22722715%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22722715%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

12

H M Lokhorst

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22722715%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

6

B van der Holt

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22722715%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

R Kuiper

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22722715%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

A Broyl

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22722715%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Y de Knegt

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22722715%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

M H van Vliet

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22722715%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

E H van Beers

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22722715%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

L el Jarari

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22722715%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

G Mulligan

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22722715%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

W Gregory

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22722715%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

H Goldschmidt

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22722715%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

M van Duin

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22722715%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

P Sonneveld

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22722715%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

publication date

8 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22722715%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22722715%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22722715%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22722715%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

2406-2413

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22722715%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

cites work

Ultra high-risk myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Molecular pathogenesis and a consequent classification of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

The molecular classification of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Bioconductor: open software development for computational biology and bioinformatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Adjusting batch effects in microarray expression data using empirical Bayes methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Activation of STAT1 is required for interferon-alpha-mediated cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

A comparison of oligonucleotide and cDNA-based microarray systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du M

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127

Prediction by Supervised Principal Components

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.127